Incyte Corp | INCY

Stock Price
62.37
Daily Change
-0.27%
Yearly
-15.59%
Q2 Forecast
60.73
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 23.97 -0.64 -2.60% 41.58%
Agenus 1.73 0.13 8.13% 10.90%
Agios Pharmaceuticals 26.06 0.01 0.04% 42.33%
Alnylam Pharmaceuticals 192.30 -1.37 -0.71% 46.09%
Amgen 221.88 3.81 1.75% -9.60%
BioCryst Pharmaceuticals 8.36 0.01 0.12% -19.69%
Biogen 302.13 1.93 0.64% 53.28%
Bluebird Bio 3.71 0.08 2.20% 24.50%
BioMarin Pharmaceutical 91.73 -1.63 -1.75% 20.57%
Bristol-Myers Squibb 65.98 0.32 0.49% -12.32%
CTI Biopharma 9.05 0 0% 73.70%
Exelixis 19.48 0.29 1.51% 3.73%
Gilead Sciences 77.70 -0.17 -0.22% 25.26%
Intercept Pharmaceuticals 11.19 0.07 0.63% -23.46%
Aceragen 1.62 -0.05 -2.99% -87.08%
Incyte Corp 62.37 -0.17 -0.27% -15.59%
Ionis Pharmaceuticals 42.26 0.51 1.22% 24.22%
Eli Lilly 444.26 1.93 0.44% 46.45%
MacroGenics 5.02 0.16 3.29% 64.05%
Merck & Co 113.11 0.59 0.52% 25.90%
Moderna 128.90 -1.61 -1.23% -7.93%
Mirati Therapeutics 39.41 1.15 3.01% -8.69%
Neurocrine Biosciences 93.86 1.54 1.67% -0.32%
Nektar Therapeutics 0.61 -0.01 -1.50% -82.82%
Lumos Pharma Inc. 3.89 0.01 0.26% -47.43%
Novartis 90.38 1.01 1.13% 5.18%
Novartis 99.37 0.46 0.47% 12.07%
Puma Biotechnology 3.57 0.02 0.56% 49.37%
Pfizer 38.65 0.29 0.76% -27.43%
PTC Therapeutics 42.57 -1.55 -3.51% 58.02%
Ultragenyx Pharmaceutical 51.25 0.40 0.79% 4.04%
Regeneron Pharmaceuticals 751.22 10.32 1.39% 23.35%
Seattle Genetics 195.19 -0.19 -0.10% 36.96%
Sarepta Therapeutics 126.17 1.01 0.81% 80.22%
Vertex Pharmaceuticals 334.47 0.64 0.19% 24.80%

Indexes Price Day Year
USND 13229 -11.34 -0.09% 9.68%
US500 4274 -8.58 -0.20% 3.70%

Incyte Corp

Incyte Corp traded at $62.37 this Monday June 5th, decreasing $0.17 or 0.27 percent since the previous trading session. Looking back, over the last four weeks, Incyte Corp lost 5.20 percent. Over the last 12 months, its price fell by 15.59 percent. Looking ahead, we forecast Incyte Corp to be priced at 60.73 by the end of this quarter and at 55.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.